Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 11/20 | 0.84 |
| ▸ | FLT4 | P35916 | 11/20 | 0.84 |
| ▸ | KDR | P35968 | 11/20 | 0.84 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9176789 | 1.00 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL10989349 | 0.92 | FLT1 (1.00) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL9176266 | 0.92 | PTGS2 (0.78) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL24224258 | 0.87 | FLT1 (0.84) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL7287948 | 0.85 | FLT1 (0.87) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL9014174 | 0.85 | FLT1 (0.87) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL23447714 | 0.84 | KMT2A (0.73) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL3396415 | 0.84 | PTGS2 (0.68) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL5931087 | 0.83 | PTGS2 (0.71) | FLT1FLT4KDRL3MBTL1PTGS2 | |
| SCHEMBL9176247 | 0.83 | FLT1 (1.00) | FLT1FLT4KDRL3MBTL1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212134-B2 | Inhibitors of viral entry into mammalian cells | MICROBIOTIX, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130331456-A1 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | MICROBIOTIX, INC. | 2013-12-12 | — | — | US | disclosed |
| EP-2616073-A2 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | Microbiotix, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037119-A2 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | MICROBIOTIX, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331456-A1 | INHIBITORS OF VIRAL ENTRY INTO MAMMALIAN CELLS | HAVCR2, PIGS, ZC3HAV1 | FLT1 4044/4885FLT4 3356/4885KDR 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.